- TRADE NAME: Brukinsa (BeiGene)
- INDICATIONS: Adult patients with mantle cell lymphoma who have received at least one prior therapy.
- CLASS: Bruton's tyrosine kinase (BTK) inhibitor, Kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: ~2–4 hours
- FDA APPROVAL DATE: 11/14/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inhibitors and CYP3A inducers - PREGNANCY: Can cause fetal harm. Advise women of the potential risk to a fetus and to avoid pregnancy.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 05/15/2025
